Akero Therapeutics, Inc   Report issue

For profit Phase 2 Phase 3
Founded: South San Francisco CA United States (2017)

Organization Overview

First Clinical Trial
2019
NCT03976401
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Akero Therapeutics, Inc

Active Ingredients

Drugs in Phase 3 Trials (1)

efruxifermin (3 trials)

Drugs in Phase 2 Trials (1)

amg 876 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2